News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
408,391 Results
Type
Article (32814)
Company Profile (64)
Press Release (375506)
Multimedia
Podcasts (63)
Webinars (7)
Section
Business (113189)
Career Advice (1334)
Deals (24121)
Drug Delivery (99)
Drug Development (59982)
Employer Resources (105)
FDA (10134)
Job Trends (9124)
News (212474)
Policy (25709)
Tag
Academia (1847)
Accelerated approval (15)
Adcomms (25)
Allergies (92)
Alliances (42407)
ALS (94)
Alzheimer's disease (1259)
Antibody-drug conjugate (ADC) (184)
Approvals (10175)
Artificial intelligence (272)
Autoimmune disease (51)
Automation (15)
Bankruptcy (238)
Best Places to Work (7694)
BIOSECURE Act (16)
Biosimilars (121)
Biotechnology (42)
Bladder cancer (92)
Brain cancer (47)
Breast cancer (343)
Cancer (2864)
Cardiovascular disease (232)
Career advice (1135)
Career pathing (23)
CAR-T (162)
CDC (51)
Cell therapy (433)
Cervical cancer (23)
Clinical research (49947)
Collaboration (1100)
Company closure (3)
Compensation (782)
Complete response letters (42)
COVID-19 (2568)
CRISPR (54)
C-suite (280)
Cystic fibrosis (77)
Data (3316)
Decentralized trials (1)
Denatured (10)
Depression (76)
Diabetes (342)
Diagnostics (3669)
Digital health (19)
Diversity (7)
Diversity, equity & inclusion (34)
Drug discovery (141)
Drug pricing (150)
Drug shortages (31)
Duchenne muscular dystrophy (162)
Earnings (42056)
Editorial (46)
Employer branding (13)
Employer resources (98)
Events (47605)
Executive appointments (416)
FDA (11914)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (768)
Gene editing (112)
Generative AI (24)
Gene therapy (377)
GLP-1 (849)
Government (4313)
Grass and pollen (6)
Guidances (291)
Healthcare (11431)
HIV (40)
Huntington's disease (31)
IgA nephropathy (51)
Immunology and inflammation (149)
Immuno-oncology (16)
Indications (44)
Infectious disease (2789)
Inflammatory bowel disease (104)
Inflation Reduction Act (11)
Influenza (91)
Intellectual property (123)
Interviews (233)
IPO (10533)
IRA (45)
Job creations (1756)
Job search strategy (961)
Kidney cancer (10)
Labor market (42)
Layoffs (328)
Leadership (18)
Legal (7089)
Liver cancer (62)
Longevity (11)
Lung cancer (425)
Lymphoma (201)
Machine learning (27)
Management (33)
Manufacturing (430)
MASH (111)
Medical device (6052)
Medtech (6066)
Mergers & acquisitions (14305)
Metabolic disorders (899)
Multiple sclerosis (91)
NASH (20)
Neurodegenerative disease (147)
Neuropsychiatric disorders (42)
Neuroscience (1961)
NextGen: Class of 2025 (3663)
Non-profit (2782)
Now hiring (9)
Obesity (457)
Opinion (225)
Ovarian cancer (90)
Pain (92)
Pancreatic cancer (141)
Parkinson's disease (174)
Partnered (18)
Patents (262)
Patient recruitment (193)
Peanut (40)
People (25406)
Pharmaceutical (20)
Pharmacy benefit managers (17)
Phase I (15078)
Phase II (21680)
Phase III (17616)
Pipeline (2107)
Policy (236)
Postmarket research (1846)
Preclinical (6291)
Press Release (28)
Prostate cancer (149)
Psychedelics (39)
Radiopharmaceuticals (224)
Rare diseases (460)
Real estate (2598)
Recruiting (47)
Regulatory (17177)
Reports (24)
Research institute (1612)
Resumes & cover letters (197)
Rett syndrome (15)
RNA editing (6)
RSV (71)
Schizophrenia (106)
Series A (108)
Series B (82)
Service/supplier (4)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (140)
Sponsored (23)
Startups (1903)
State (1)
Stomach cancer (12)
Supply chain (75)
Tariffs (68)
The Weekly (52)
Vaccines (940)
Venture capital (44)
Weight loss (325)
Women's health (28)
Worklife (10)
Date
Last 7 days (439)
Last 30 days (1612)
Last 365 days (19917)
2025 (16588)
2024 (22367)
2023 (25268)
2022 (33400)
2021 (35905)
2020 (34109)
2019 (27915)
2018 (21235)
2017 (20191)
2016 (18715)
2015 (21499)
2014 (15968)
2013 (12890)
2012 (13639)
2011 (14423)
2010 (13094)
Location
Africa (578)
Alabama (41)
Alaska (3)
Arizona (110)
Arkansas (5)
Asia (26656)
Australia (4782)
California (5653)
Canada (1759)
China (620)
Colorado (224)
Connecticut (253)
Delaware (191)
Europe (63936)
Florida (862)
Georgia (187)
Hawaii (3)
Idaho (30)
Illinois (413)
India (38)
Indiana (290)
Iowa (14)
Japan (255)
Kansas (72)
Kentucky (22)
Louisiana (12)
Maine (31)
Maryland (868)
Massachusetts (4053)
Michigan (140)
Minnesota (205)
Mississippi (1)
Missouri (69)
Montana (21)
Nebraska (10)
Nevada (64)
New Hampshire (24)
New Jersey (1756)
New Mexico (15)
New York (1650)
North Carolina (698)
North Dakota (5)
Northern California (2725)
Ohio (165)
Oklahoma (9)
Oregon (11)
Pennsylvania (1183)
Puerto Rico (9)
Rhode Island (16)
South America (801)
South Carolina (24)
South Dakota (1)
Southern California (2150)
Tennessee (71)
Texas (726)
United States (20347)
Utah (133)
Virginia (149)
Washington D.C. (42)
Washington State (433)
West Virginia (2)
Wisconsin (44)
Wyoming (1)
408,391 Results for "itm isotopen technologien muenchen ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ITM Appoints Annette Breunig as Chief People Officer
October 13, 2025
·
3 min read
Press Releases
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
September 24, 2025
·
3 min read
Press Releases
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
September 12, 2025
·
7 min read
Press Releases
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
October 20, 2025
·
6 min read
Press Releases
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
October 27, 2025
·
5 min read
Press Releases
ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
October 8, 2025
·
6 min read
Press Releases
ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025
September 16, 2025
·
4 min read
Press Releases
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
October 17, 2025
·
3 min read
Press Releases
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
September 4, 2025
·
1 min read
Press Releases
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
June 23, 2025
·
6 min read
1 of 40,840
Next
